The APL Toll: How ‘SMA Research’ became a fee for admission

Here is the practice this essay is about, stated plainly before anything else. A number of Australian licensees are introducing an additional charge: before an SMA can go onto the licensee’s approved product list, the asset manager running it has to pay an extra “research fee.”

Not a standard cost applied evenly across the shelf. Not something the licensee funds out of its own pocket as part of running a licence. A fee charged specifically to the manager whose product is trying to get admitted, charged specifically because it is trying to get admitted.

That is the entire mechanism. Everything else in this piece, the RG 97 exposure, the cookie-cutter case law, the in-house double standard, the personalisation gap, is downstream of that one sentence. If the essay ever gets vague from here, it has failed at the one job it has.

What the fee actually buys

Call the thing what it is. This is an admission fee, a toll for a listing. Pay it, and the product is eligible to sit on the approved product list in front of advisers and, eventually, clients. Don’t pay it, and it isn’t, no matter how the product performs.

Licensees will describe this as extra due diligence, a governance uplift, additional scrutiny that protects advisers from recommending something under-researched.

That description might even be true of the analysis itself. It is not true of the fee.

A genuine governance cost, funded by the licensee as part of the price of holding a licence, is one thing. A charge payable as a condition of entry is a different thing wearing the same paperwork. The first is diligence. The second is rent extraction from anyone who wants a place on the shelf, and the “research” label is doing the work of making that extraction look like professional care.

It’s the same model as an app store charging developers extra to get featured, except an app store doesn’t also claim the fee makes the app safer for the user. Here, the charge is marketed as if it does exactly that.

A toll wearing a compliance badge

Once you see it for what it is, its regulatory status stops being ambiguous.

A payment a manager must make to get a product in front of advisers and clients is not neutral. It functions exactly like a platform rebate or old-school retail slotting fee: the manager pays the intermediary, the intermediary controls the shelf, and the client is steered toward whatever cleared the gate, without ever seeing that a gate existed.

ASIC’s RG 97, the regulatory guide setting out how licensees and product issuers must disclose fees and costs to clients, already treats this category of cost as disclosable.

Distribution costs are explicitly folded into the administration fees and costs that trustees, responsible entities and platform operators must show clients, precisely because they are costs the investor ultimately wears, whether the fee is visible to them or not.

A charge levied to get onto an APL is a distribution cost by any economic definition. Calling it “research” doesn’t change what it’s for.

It also sits awkwardly against best interest duty, the Corporations Act obligation requiring advice to actually serve the client rather than merely comply on paper. Section 961B requires advice to be given in the client’s best interests. Section 961G requires it to be “appropriate” for that specific client.

Neither obligation bends around the fact that a product’s presence on the shelf was determined, in part, by whether its manager paid a fee rather than by how the product might suit any particular client.

If a client could reasonably expect that payment to influence which products even reach their adviser, that’s a conflict sitting inside the product list itself, before advice has begun.

Where the law could actually bite

Three distinct regulatory exposures follow from this, and licensees weighing whether to introduce or keep one of these fees should treat them as live, not theoretical.

First, an RG 97 disclosure failure: if the fee isn’t clearly itemised as a distribution cost, ASIC has an established framework for treating that as non-compliant fee and cost disclosure, not a grey area it has yet to consider.

Second, conflicted remuneration scrutiny: a fee structured so that payment (or non-payment, in the in-house case) shapes which products reach advisers looks, functionally, like the kind of arrangement sections 963A, 963E and 963J were written to catch, regardless of what it’s labelled internally.

Third, and most serious, a best interest duty failure built on top of an APL shaped by tolls, where an adviser’s individually reasoned recommendation turns out to rest on a shelf that was never neutral to begin with.

None of this means a court would treat an admission-fee case identically to DOD Bookkeeping; that case turned on its own facts.

What it does mean is that a Federal Court has recently shown it will look past professional-looking paperwork to the economics sitting underneath it once a matter is litigated, and an admission fee is exactly the kind of paperwork that invites the same scrutiny.

Cookie-cutter advice gets a research footnote

Australia already has a recent, concrete example of this dynamic playing out at the advice layer. In April 2025, the Federal Court penalised DOD Bookkeeping Pty Ltd, formerly Equiti Financial Services, $11.03 million.

The pattern: templated SMSF advice pushing clients toward property, backed by conflicted bonus payments to the advisers making the recommendation.

ASIC pursued the licensee under section 961K, which makes it responsible for representatives who breach best interest duty or fail to give appropriate advice. Justice Goodman’s assessment was blunt: “little or no heed was paid to the particular circumstances of the clients.”

That case involved property spruiking through SMSFs, not an SMA admission fee, and the fact patterns shouldn’t be conflated.

But the underlying shape, product chosen for its economics first, thin client-specific reasoning bolted on afterward, is the same shape an admission-toll APL produces further upstream.

Once a product is on the shelf because its manager paid to be there, and the shelf is then marketed to advisers as pre-vetted, the advice built on top of it inherits the same risk the Court punished: paperwork that looks rigorous while saying almost nothing about the client actually sitting in the room.

Two shelves, one admission fee

This gets worse the moment a licensee also manufactures its own SMAs, because the toll then only applies to half the shelf.

External managers pay to get their SMA in front of advisers. In-house SMAs don’t, because the licensee doesn’t need to charge itself to admit its own product to its own list. It was never outside the gate in the first place.

That’s not a subtle difference in treatment. It’s a structural exemption built into the shelf, and it means the fee isn’t functioning as quality control at all, since the products least subject to it are the ones the licensee has the strongest commercial incentive to push.

Best interest duty asks the adviser to select purely on client fit. In practice, one category of product arrived by paying a charge that signals nothing about suitability, and the other arrived by internal fiat and paid nothing. Neither fact is generally disclosed to the client choosing between them.

The fee was never going to personalise anything

Here’s what holds even in the best-case version of this story, fully disclosed, no conflicted funding anywhere in the chain. It still wouldn’t fix the actual compliance problem, because it was never structured to touch it.

Personalising advice isn’t a lookup against a product research note. It’s a multi-dimensional read of one specific product against one specific client: their balance sheet, tax position, timeframe, capacity to absorb loss, how they behave when markets fall hard.

That analysis happens one relationship at a time, at the point of advice. Product-level research, however well-funded, answers a narrower question: how the SMA is built, what risk it carries, how fees and tax fall out for a generic holder.

It cannot answer the client-specific question, because it’s performed once, before any client exists to test the product against. An admission fee only ever buys the first kind of answer. The second was always the adviser’s job, and no amount charged for shelf entry was ever going to do it for them.

So when a licensee charges this fee and markets it as protecting advice quality, it’s charging for a layer one step removed from the layer that actually creates liability.

Call it what it is: margin theatre. And an admission fee is a worse version of that theatre than ordinary research funding would be, because it leaves a specific, dated, traceable transaction behind.

A licensee later asked, in a review or a courtroom, what that payment actually bought for any individual client isn’t holding a shield. It’s holding a receipt for shelf space, stamped with the word “research.”

What this means for advisers right now

None of this is only a licensee governance problem. It changes what an adviser can safely rely on today.

“It’s on the APL and it’s been researched” is not, by itself, evidence that a recommendation meets best interest duty, because the research behind that listing was never designed to test suitability for the client in front of you. Two practical implications follow.

File notes and statements of advice should show client-specific reasoning that goes beyond list membership: why this structure, for this client, compared with realistic alternatives, not just confirmation that the product cleared the shelf.

And where an adviser has reason to suspect the APL itself may be shaped by admission economics rather than pure merit, that’s worth naming in the file, not glossing over, since it’s the adviser’s own PI exposure sitting behind the licensee’s fee structure, not just the licensee’s.

Who sees the toll

Strip the governance language away and this is an information asymmetry problem, the same shape as any market where one party controls the pricing data and the other two don’t.

The licensee sees the full picture: which managers paid, how much, and which products skipped the charge entirely because the licensee owns them. The adviser sees a curated outcome, a product that’s “on the list” and “well-researched,” with the fee abstracted into a governance process they’re trained to trust. The client sees nothing: not the fee, not the in-house exemption, not the fact that admission was a paid transaction rather than a judgement about suitability for them specifically.

Three parties, three different pictures of the same shelf, and only one of them knows the other two are working from an incomplete one. That’s precisely what RG 97 exists to prevent, and precisely why an undisclosed or vaguely disclosed fee sits so badly against its purpose.

Why the model is backwards

Flip the incentives around and they’re uncomfortable no matter which direction the money moves. If a manager pays, they’ve bought shelf space, and advisers get nudged toward the product by infrastructure they never had reason to question.

If a manager doesn’t or can’t pay, a potentially suitable product for some clients never reaches the shelf at all, filtered out by price of entry rather than quality.

Either way, the client bears the cost eventually, through fees, through a narrower shelf, through advice built on a list shaped before the adviser ever opened a file. Only the licensee can see that clearly enough to know it.

The choice

Product research isn’t the centre of advice. The client is, and the Corporations Act has always said so.

A licensee charging managers for APL entry is building its business around the shelf. A licensee that absorbs the true cost of governance itself, as a baseline cost of holding a licence, and pushes personalisation back onto advisers where the law already places it, is building around the client instead. Only one of those models can be funded by charging at the door.

Four things would actually fix this, starting now, not after the next enforcement action:

• Disclose the fee explicitly as a distribution cost under RG 97, itemised per product, not buried in an aggregate line.
• End the differential treatment between in-house and externally admitted SMAs, or disclose the difference as plainly as the fee itself.
• Redirect the spend from an admission toll into licensee-funded governance that doesn’t gate market access at all.
• Require advice files to demonstrate client-level fit beyond APL membership, so “researched” stops functioning as a substitute for reasoning.

The DOD Bookkeeping judgment shows a court willing to look straight through professional-looking paperwork to the economics underneath it. The only real choice left for licensees running one of these fees is whether to get ahead of that themselves, or wait for a regulator to read the invoice the same way this essay just did.